On 20 February 2007, orphan designation (EU/3/07/432) was granted by the European Commission to Quintiles UK Limited, United Kingdom, for ex-vivo cultured adult human mesenchymal stem cells for the treatment of graft-versus-host disease.
The sponsorship was transferred to Genzyme Europe BV, the Netherlands, in October 2009 and to Voisin Consulting S.A.R.L., France, in February 2013.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
Ex-vivo cultured adult human mesenchymal stem cells
|Disease / condition||
Treatment of graft-versus-host disease
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.